Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Market capitalization
19.84 MAUD
—
—
−0.017AUD
−3.79 MAUD
1.80 MAUD
190.69 M
Beta (1Y)
2.15
About IMMURON LIMITED
Sector
CEO
Steven Lydeamore
Headquarters
Carlton
Website
Founded
1994
ISIN
AU000000IMC7
FIGI
BBG000C6G8P0
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
0.00
$IMRNImmuron stock rockets after funding by U.S. DoD of new research agreementShares of Immuron Ltd. IMRN, +46.18% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Departme
Long
11
About to breakout !!The Company www.immuron.com.auImmuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we be
Long
11
ASX:IMCIMC - Break of LT DT - finding base watching
IMC Covid-19 Simple Solution ?themarketherald.com.au Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus The company tested its IMM-124E treatment and has seen antiviral activity against SARS-CoV-2, the virus th
Long
Immuron’s products found to neutralise Covid-19Immuron’s commercially available products found to neutralise COVID-19 during in vitro researchsmallcaps.com.auImmuron’s commercially available products found to neutralise COVID-19 during in vitro researchByLorna Nicholas -July 21, 2020Immuron ASX IMC NASDAQ IMRN SARS-CoV-2 COVID-19 antivi
Long
11
NMRC received guidance from the FDA NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC-Two human phase II clinical trials to be conducted in 2021-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobact
IMRNLooks like a big wave is coming, announced new partnership what do you guys think?
Long
NMRC Requests Meeting with FDA for Guidance on two Phase 2 trialUS DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious DiarrheaKey PointsNMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETECTwo human phase II clinical trials
11
rwerewewrrwer
33
IMC long positionUp trending everywhere i dont know if this will work out. But i'm trying to learn.
Long
Keep reading
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Featured
4.4Very Good
Learn more
TradeStation
4.4Very Good
Learn more
The current price of
IMC
is
0.090
AUD
— it has increased by
3.45
% in the past 24 hours. Watch
IMMURON LIMITED
stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on
ASX
exchange
IMMURON LIMITED
stocks are traded under the ticker
IMC
.
IMC
stock has risen by
5.88
% compared to the previous week, the month change is a
2.17
% fall, over the last year
IMMURON LIMITED
has showed a
30.43
% increase.
IMC
reached its all-time high on
Aug 13, 2009
with the price of
3.219
AUD
, and its all-time low was
0.050
AUD
and was reached on
Mar 25, 2020
. View more price dynamics on
IMC chart.
See other stocks reaching their highest and lowest prices.
IMC
stock is
3.45
% volatile and has beta coefficient of
2.15
. Track
IMMURON LIMITED
stock price on the chart and check out the list of the most volatile stocks — is
IMMURON LIMITED
there?
Today
IMMURON LIMITED
has the market capitalization of
19.84 M
, it has decreased by
3.53
% over the last week.
Yes, you can track
IMMURON LIMITED financialsin yearly and quarterly reports right on TradingView.
IMMURON LIMITED
is going to release the next earnings report on
Aug 30, 2024
. Keep track of upcoming events with our Earnings Calendar.
IMC
net income for the last half-year is
−2.07 M
AUD
, while the previous report showed
−1.81 M
AUD
of net income which accounts for
−14.66
% change. Track more
IMMURON LIMITED financial statsto get the full picture.
No,
IMC
doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks,
IMC
shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade
IMMURON LIMITED
stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So
IMMURON LIMITED
technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating
IMMURON LIMITED
stock shows the sell signal. See more of
IMMURON LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
